Acrivon Therapeutics (NASDAQ:ACRV) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Acrivon Therapeutics (NASDAQ:ACRVFree Report) in a report released on Thursday, Benzinga reports. The firm currently has a $20.00 price objective on the stock.

Separately, JMP Securities started coverage on Acrivon Therapeutics in a report on Friday, March 1st. They issued a mkt outperform rating and a $14.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to, Acrivon Therapeutics currently has a consensus rating of Buy and an average target price of $22.14.

Get Our Latest Report on Acrivon Therapeutics

Acrivon Therapeutics Price Performance

Shares of NASDAQ:ACRV opened at $7.15 on Thursday. Acrivon Therapeutics has a 1-year low of $3.19 and a 1-year high of $14.39. The business has a fifty day moving average price of $4.63 and a 200-day moving average price of $5.48. The company has a market capitalization of $158.66 million, a PE ratio of -2.68 and a beta of 1.70.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. New York State Common Retirement Fund purchased a new position in Acrivon Therapeutics in the first quarter worth about $28,000. Citigroup Inc. boosted its position in Acrivon Therapeutics by 1,281.2% in the second quarter. Citigroup Inc. now owns 2,790 shares of the company’s stock worth $36,000 after purchasing an additional 2,588 shares during the last quarter. California State Teachers Retirement System purchased a new position in shares of Acrivon Therapeutics during the 1st quarter valued at about $41,000. Wells Fargo & Company MN lifted its position in shares of Acrivon Therapeutics by 108.1% during the 2nd quarter. Wells Fargo & Company MN now owns 3,305 shares of the company’s stock valued at $43,000 after buying an additional 1,717 shares in the last quarter. Finally, Barclays PLC purchased a new position in shares of Acrivon Therapeutics during the 4th quarter valued at about $47,000. 71.62% of the stock is owned by hedge funds and other institutional investors.

About Acrivon Therapeutics

(Get Free Report)

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Further Reading

Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with's FREE daily email newsletter.